BB Adamant Global Biotech (CH)
Biotech sector with sustainable, strong sales and earnings growth thanks to high innovation level
Expiring patents of pharma companies lead to high M&A activity (patent cliff)
Valuations very attractive on historical average over the last 10 years
Please find a more detailed description of share classes here.
The BB Adamant Global Biotech fund focuses on the most promising companies in the biotechnology sector. The fund invests in 30 to 50 stocks that have met all of the stringent selection criteria applied by us.
Indexed performance (as at: 24.09.2021)
NAV: CHF 4'236.20 (23.09.2021)
Rolling performance (23.09.2021)
|23.09.2020 - 23.09.2021||26.59%||30.12%|
|23.09.2019 - 23.09.2020||16.93%||17.82%|
|23.09.2018 - 23.09.2019||-8.78%||-9.18%|
|23.09.2017 - 23.09.2018||2.05%||6.34%|
Annualized performance (23.09.2021)
|Since Inception p.a.||14.10%||17.11%|
Cumulative performance (23.09.2021)
Facts & Key figures
The BB Adamant Global Biotech fund focuses on the most promising companies in the biotechnology sector. The fund invests in 30 to 50 stocks that have met all of the stringent selection criteria appliedby us. These are biotech companies that have specialized in areas such as immunology, virology, neurology, oncology, cardiology, endocrinology, etc. Geographically, the fund’s investments are concentrated in North America, Europe and Asia.Show moreShow less
Investment suitability & Risk
|Investment Manager||Bellevue Asset Management AG|
|Fund Administrator||Swisscanto Fondsleitung AG|
|Auditor||Ernst & Young AG|
|Year end closing||30. Sep|
|NAV Calculation||Daily "Forward Pricing"|
|Cut of time||15:00 CET|
|Subscription Fee (max.)||2.50%|
|Performance Fee||10.00% (with High Water Mark)|
Key data (31.08.2021, base currency CHF)
|No. of positions||56|
Top 10 positions
Breakdown by sector
Opportunities & Risks
- New innovative drugs are powering sustainable momentum in the biotech sector.
- Attractively valued large-cap biotechs.
- Expiring pharmaceutical patents trigger a rise in M&A activity.
- Focus on US biotech companies with strong growth potential.
- Healthcare pioneer since 1993 and today one of the biggest independent investors in the sector in Europe.
- Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Market, industry or company factors can lead to strong short-term price fluctuations.
- Investments in foreign currencies are subject to currency risks.
- Investing in emerging markets entails the additional risk of political and social instability.
- The fund may invest in financial instruments that might have a rather low level of liquidity, which can in turn affect the fund’s liquidity.
Review / Outlook
Global stock markets marched higher in August. The S&P Index ended the month 3.0% higher, while the Nasdaq Biotech Index showed a gain of 4.2%.
The re-opening of the global economy continued in August. Many industrialized countries have eased their pandemic restrictions and this was reflected in the good economic data published in August. However, the rapid spread of the delta variant, which has caused new cases to climb, especially among unvaccinated people, is a cause for concern. Data from the UK and Israel suggest that vaccine effectiveness declines about six to eight months after vaccination. For this reason, some countries have begun to administer a booster dose to particularly vulnerable people. The US central bank said it could start to dial back its expansionary monetary policy sometime this year, but any such action would depend on a further improvement in employment data and the repercussions of the delta variant.
The following companies made the best contribution to the portfolio's performance in August: Early in the month Regeneron reported strong quarterly results, driven by the sales of its REGEN-CoV antibody cocktail for COVID-19 patients. The New York-based biotech company also benefited from good news about Dupixent and Eylea, two drugs that were developed in collaboration with business partners. Seagen added a second bladder cancer program to its pipeline by acquiring rights to a HER2 antibody drug conjugate (ADC) from RemeGen. Alnylam, a specialist in RNAi therapeutics, was marked up after publishing strong sales for its approved products Onpattro, Givlaari and Oxlumo, and it increased its sales guidance for the current fiscal year.
Immuno-oncology firm Beigene was a performance detractor. Its shares retreated in the wake of political action in China and the repercussions that had on the country's stock market. This political action also pressured the shares of two other companies in the portfolio, Innovent and Zai Labs. Jazz Pharmaceuticals plunged after releasing its quarterly results, which raised fears of generic competition gaining entry into the narcolepsy market. Fate Therapeutics presented good data for its B-cell lymphoma program, but could not beat investors’ high expectations.
We sold Dicerna, Jazz, Acadia shares and invested the proceeds in companies such as Harmony Biosciences and Kymera Therapeutics.
Our stance towards the biotech sector remains positive in view of its strong fundamentals and very attractive valuations (average 2022 P/E of 14x and PEG of 1.1 for large caps). These are still very attractive multiples compared to the biotech sector's historical valuations and the current ratios for the pharma sector (P/E 16x, PEG 2.4) and the S&P Index (P/E 21x, PEG 2.1).
The companies in our portfolio are working on technologies or products for novel treatment solutions. We are also invested in selected specialty pharma companies that offer high growth rates and moderate valuations. The BB Adamant Global Biotech Fund is well-positioned to profit from the milestones that are expected to be reached in 2021 and 2022. The regulatory environment favors the innovation coming out of biotech labs and the coronavirus crisis has improved the image of drug developers. Large pharma companies have acquired a number of companies in the fund's portfolio – Loxo, Array, Medicines Company, Myokardia and Alexion – and we expect more M&A deals to be announced during the coming months.
Past performance is not a reliable indicator of future results and can be misleading. As the sub-fund is denominated in a currency that may differ than an investor’s base currency, changes in the rate of exchange may have an adverse effect on prices and incomes. Performance is shown net of fees and expenses for the relevant share class over the reference period. All performance figures reflect the reinvestment of dividends and do not take into account the commissions and costs incurred on the issue and redemption of shares, if any. Individual costs are not taken into account and would have a negative impact on the performance. With an investment amount of EUR 1,000 over an investment period of five years, the investment result in the first year would be reduced by the front-end load of up to EUR 50 (5%) as well as by additional individual custody charges. In subsequent years, the investment result would also be reduced by the individual custody account costs incurred. The reference benchmark of this class is used for performance comparison purposes only (dividend reinvested). No benchmark is directly identical to a sub-fund, thus the performance of a benchmark is not a reliable indicator of future performance of the sub-fund it is compared to. There can be no assurance that a return will be achieved or that a substantial loss of capital will not be incurred. All figures in base currency in %, calculated by the total return / BVI method.Show moreShow less